FDA Oncology - OCE's Project Facilitate processed 401 calls and 889 applications for oncology investigational drugs
FDA Oncology
oncodaily.com/57068.html
#Cancer #Cancer Drugs #FDAOncology #OncoDaily #Oncology #OCEAnnualReport
In 2023, OCE's #ProjectFacilitate handled 401 phone calls and 889 Expanded Access applications for oncology investigational drugs. Learn more in the #OCEAnnualReport .
fda.gov/about-fda/2023…
#CancerMoonshot #OCEAnnualReport
Available now—the Oncology Center of Excellence 2023 Annual Report, highlighting work with external stakeholders & within U.S. FDA to advance the development and regulation of oncology products for patients with cancer. fda.gov/about-fda/oce-…
#OCEAnnualReport
#CancerMoonshot
New! Read OCE's Annual Report on driving change in oncology product development for the benefit of patients with cancer. #OCEAnnualReport #EndCancerAsWeKnowIt
fda.gov/about-fda/onco…
Want to know more about #FDAOncology and its broad range of review, science, engagement, and policy efforts? Check out OCE’s 2021 Annual Report.
#OCEAnnualReport #EndCancerAsWeKnowIt
fda.gov/about-fda/onco…
The Regulatory Review section of the 2022 #OCEAnnualReport includes approval highlights for cancer drugs, biologics & cellular therapies, and devices. Plus #ProjectOrbis #PediatricOnc #RareCancersProgram #AcceleratedApproval #OCEProjectConfirm #RTOR
fda.gov/about-fda/2022…
Project Orbis remains an active OCE program with 19 unique approvals in 2023. Learn more in the Project Orbis section of the #OCEAnnualReport .
fda.gov/about-fda/2023…
#CancerMoonshot
Highlights of oncology products approved in 2023, plus updates on #ProjectOrbis #PediatricOnc #RareCancersProgram #AcceleratedApproval #OCEProjectConfirm #RTOR .
Learn more - OCE Annual Report: fda.gov/about-fda/2023…
#CancerMoonshot #OCEAnnualReport
The OCE is committed to rigorous product reviews, research & development to increase knowledge resulting in better outcomes for patients, and outreach to encourage collaborative, patient-centered discussion. Find out more in the #OCEAnnualReport
fda.gov/about-fda/onco…
In 2023, OCE's #ProjectFacilitate handled 401 phone calls and 889 Expanded Access applications. Learn more in the #OCEAnnualReport .
fda.gov/about-fda/2023…
#CancerMoonshot #OCEAnnualReport
Project Community leads our outreach to patients with cancer in the US, their families and caregivers, and medically underserved communities. Learn more about #OCEProjectCommunity in our 2022 #OCEAnnualReport . ⤵️
fda.gov/about-fda/2022…
Fostering diversity in oncology drug development is an important part of the OCE's work. Learn more in the #OCEAnnualReport . ⤵️
fda.gov/about-fda/2023…
#CancerMoonshot #OCEProjectCommunity #OCEProjectEquity #OCEProjectASIATICA
OCE's Annual Report provides updates on patient-focused regulatory projects: #OCEPFDD #OCERWE #PrecisionOncology #ProjectEndpoint #OCEProjectOptimus #ProjectPragmatica #ProjectSiteSelector 🔽
fda.gov/about-fda/2023…
#CancerMoonshot #OCEAnnualReport
In 2023, #OCEProjectSocrates supported a variety of professional education resources in oncology/hematology: fellowships, workshops, and webinars. Learn more in the #OCEAnnualReport 🔽
fda.gov/about-fda/2023…
#CancerMoonshot
Find out more about OCE's Patient-Focused Drug Development Program, in the #OCEAnnualReport .
fda.gov/about-fda/2023…
#CancerMoonshot #OCEPFDD
ICYMI: Read OCE's Annual Report on driving change in oncology product development for the benefit of patients with cancer. #OCEAnnualReport #CancerMoonshot
fda.gov/about-fda/2021…
OCE's Richard Pazdur, MD: 'The OCE is committed to driving change in cancer drug development that results in more efficient & accessible clinical trials, more effective & safer medical products, & better outcomes for patients with cancer.' #OCEAnnualReport
fda.gov/about-fda/2021…
Learn about Project ASIATICA's efforts in 2023 to bring greater awareness of health challenges facing AA & NHPI patients with cancer and advance health equity for these populations.
fda.gov/about-fda/2023…
#CancerMoonshot #OCEProjectASIATICA #OCEAnnualReport
Oncology Regulatory Review: 2021 Highlights from the FDA Oncology Center of Excellence. #ProjectOrbis #PediatricOncology #OCEPFDD #OCEAnnualReport
fda.gov/about-fda/2021…
In only its 3rd year, #OCEProjectSocrates supported a variety of professional education resources in oncology/hematology: fellowships, workshops, and webinars. Learn more in the #OCEAnnualReport 🔽
fda.gov/about-fda/2022…